Clinical Trial

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-18; most recent amendment 2025-12-23.
Status change: Not Yet Recruiting → Recruiting 2025-12-23
Trial Details
NCT Number NCT07249346
Lead Sponsor Hannah Choe, MD
Collaborators: Incyte Corporation
Conditions Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
Enrollment 124 participants
Start Date 2026-06-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-24